Prostate cancer cells can adapt to androgen deprivation and restore androgen receptor signaling, eventually progressing to CRPC, even CRPC-NE, which is a lethal subtype of PCa with extremely poor survival rate (4–6). This evidence concerns the gene AR and prostate carcinoma.